Swiss Life Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Sell |
28,220
-2,305
| -8% | -$1.57M | 0.07% | 196 |
|
|
2026
Q1 | $14.1M | Buy |
30,525
+19,763
| +184% | +$15.1M | 0.07% | 223 |
|
|
2025
Q4 | $8.31M | Sell |
10,762
-12,896
| -55% | -$8.76M | 0.04% | 304 |
|
|
2025
Q3 | $13.3M | Buy |
23,658
+12,500
| +112% | +$7.07M | 0.07% | 220 |
|
|
2025
Q2 | $5.86M | Buy |
11,158
+754
| +7% | +$421K | 0.03% | 335 |
|
|
2025
Q1 | $6.6M | Buy |
10,404
+1,226
| +13% | +$843K | 0.05% | 298 |
|
|
2024
Q4 | $6.53M | Sell |
9,178
-486
| -5% | -$408K | 0.05% | 270 |
|
|
2024
Q3 | $10.2M | Buy |
9,664
+1,696
| +21% | +$1.89M | 0.12% | 171 |
|
|
2024
Q2 | $8.37M | Buy |
7,968
+1,661
| +26% | +$1.61M | 0.1% | 180 |
|
|
2024
Q1 | $6.07M | Sell |
6,307
-12,317
| -66% | -$11.7M | 0.08% | 197 |
|
|
2023
Q4 | $16.4M | Sell |
18,624
-9,027
| -33% | -$7.43M | 0.2% | 115 |
|
|
2023
Q3 | $22.8M | Buy |
27,651
+9,247
| +50% | +$7.27M | 0.35% | 53 |
|
|
2023
Q2 | $13.2M | Sell |
18,404
-1,208
| -6% | -$931K | 0.2% | 124 |
|
|
2023
Q1 | $16.1M | Buy |
19,612
+6,161
| +46% | +$4.65M | 0.24% | 95 |
|
|
2022
Q4 | $9.71M | Buy |
13,451
+943
| +8% | +$696K | 0.16% | 163 |
|
|
2022
Q3 | $8.62M | Sell |
12,508
-2,162
| -15% | -$1.36M | 0.15% | 172 |
|
|
2022
Q2 | $8.68M | Sell |
14,670
-4,738
| -24% | -$3.08M | 0.14% | 181 |
|
|
2022
Q1 | $13.5M | Sell |
19,408
-1,322
| -6% | -$836K | 0.19% | 119 |
|
|
2021
Q4 | $13.1M | Buy |
20,730
+4,153
| +25% | +$2.55M | 0.17% | 136 |
|
|
2021
Q3 | $10M | Buy |
16,577
+1,970
| +13% | +$1.22M | 0.14% | 182 |
|
|
2021
Q2 | $6.02M | Sell |
14,607
-2,321
| -14% | -$1.18M | 0.06% | 290 |
|
|
2021
Q1 | $8.01M | Buy |
16,928
+542
| +3% | +$264K | 0.11% | 218 |
|
|
2020
Q4 | $7.92M | Buy |
16,386
+6,629
| +68% | +$3.58M | 0.12% | 209 |
|
|
2020
Q3 | $5.46M | Sell |
9,757
-455
| -4% | -$276K | 0.08% | 184 |
|
|
2020
Q2 | $6.37M | Buy |
10,212
+7,363
| +258% | +$4.18M | 0.1% | 156 |
|
|
2020
Q1 | $1.39M | Buy |
2,849
+477
| +20% | +$197K | 0.03% | 353 |
|
|
2019
Q4 | $891K | Sell |
2,372
-752
| -24% | -$253K | 0.02% | 396 |
|
|
2019
Q3 | $867K | Buy |
3,124
+1,853
| +146% | +$548K | 0.01% | 405 |
|
|
2019
Q2 | $397K | Buy |
1,271
+626
| +97% | +$208K | ﹤0.01% | 484 |
|
|
2019
Q1 | $265K | Buy |
+645
| New | +$266K | ﹤0.01% | 478 |
|
|
2018
Q4 | – | Sell |
-808
| Closed | -$326K | – | 401 |
|
|
2018
Q3 | $326K | Sell |
808
-787
| -49% | -$300K | ﹤0.01% | 488 |
|
|
2018
Q2 | $550K | Buy |
1,595
+998
| +167% | +$312K | 0.01% | 424 |
|
|
2018
Q1 | $206K | Hold |
597
| – | – | ﹤0.01% | 477 |
|
|
2017
Q4 | $225K | Buy |
597
+134
| +29% | +$54.3K | 0.01% | 468 |
|
|
2017
Q3 | $207K | Buy |
+463
| New | +$220K | 0.01% | 443 |
|
|
2016
Q1 | – | Sell |
-917
| Closed | -$498K | – | 385 |
|
|
2015
Q4 | $498K | Buy |
917
+6
| +0.7% | +$3.25K | 0.02% | 229 |
|
|
2015
Q3 | $424K | Buy |
911
+228
| +33% | +$122K | 0.02% | 219 |
|
|
2015
Q2 | $348K | Buy |
+683
| New | +$333K | 0.01% | 227 |
|
Other funds holding REGN
N
Swiss Life Asset Management's REGN Position: Q2 2026 in Review
Swiss Life Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 7.6% in Q2 2026, selling an estimated $1.57M and leaving 28,220 shares worth $17.6M. The position accounts for 0.07% of the portfolio, ranked #196.
Swiss Life Asset Management first reported a position in REGN in Q2 2015 and has held it in 38 quarters since. The position peaked at $22.8M in Q3 2023. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Swiss Life Asset Management held 28,220 shares of Regeneron Pharmaceuticals worth $17.6M as of Q2 2026.
- Swiss Life Asset Management sold 2,305 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.57M.
- Regeneron Pharmaceuticals made up 0.07% of Swiss Life Asset Management's portfolio in Q2 2026, its #196 holding.
- Swiss Life Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- Swiss Life Asset Management's Regeneron Pharmaceuticals position peaked at $22.8M in Q3 2023.
- 955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.